Waldenström's macroglobulinemia: A review of therapy

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Waldenström's macroglobulinemia is a lymphoplasmacytic disorder characterized by a monoclonal IgM protein, anemia, hepatosplenomegaly, and hyperviscosity. With the increasing use of screening chemistry evaluations, many patients are diagnosed without symptoms and are candidates for observation with no therapeutic intervention until symptoms develop. Plasma exchange can be useful to manage hyperviscosity but does not address the infiltrative process in the bone marrow, which requires cytoreductive therapy. This review covers current regimens that have been used to manage Waldenström's macroglobulinemia, including alkylating agents, purine nucleoside analogs, and rituximab. The value of steroids, radiotherapy, stem cell transplantation, and splenectomy is also reviewed. The lack of phase III studies does not permit an algorithm that would be appropriate for all patients. Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen.

Original languageEnglish (US)
Pages (from-to)1517-1526
Number of pages10
JournalLeukemia and Lymphoma
Issue number8
StatePublished - 2002


  • Alkylating agents
  • Lymphoplasmacytic disorder
  • Monoclonal IgM protein
  • Purine nucleoside analogs
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Waldenström's macroglobulinemia: A review of therapy'. Together they form a unique fingerprint.

Cite this